Merck KGaA
MRK: XETR (DEU)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| fN@ | LOCK|?<M< | LOCK|LY%H>qc |
Merck KGaA Earnings: Weak 2026 Guidance as Patent Losses and Headwinds Weigh on Outlook
Merck KGaA reported 2.6% organic sales growth in the fourth quarter of 2025, roughly in line with the company-compiled consensus. The full-year sales increased by 3.1%, and adjusted EBITDA reached 28.9%, both of which were in line with management’s guidance. Shares were down 2% intraday.
